They suggest that patients with L-CHIP are at an increased risk of subsequently developing lymphoid malignancies, in contrast with the classical myeloid malignancy risk attributed to traditional CHIP (or “M-CHIP” in the work by Niroula and colleagues). This evidence concerns the gene STUB1 and myeloid neoplasm.